Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2 1

Status

Completed 45Unknown 12Terminated 11Active not recruiting 6Recruiting 4Not yet recruiting 4Withdrawn 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5Genitourinary 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 1Neoplasms 1Giant Cell Tumor of Bone 1Breast Diseases 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Denosumab × Clear all
NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT04067726 2026-03-31

TRIDENT

Washington University School of Medicine

Phase 2 Active not recruiting
210 enrolled
Breast

Breast Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Swiss Cancer Institute

Phase 3 Active not recruiting
1,380 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04586660 2025-10-01

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Amgen

Phase 4 Active not recruiting
36 enrolled

Giant Cell Tumor of Bone

NCT04711109 2025-04-02

BRCA-P

Alliance for Clinical Trials in Oncology

Phase 3 Active not recruiting
300 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms

NCT03324932 2023-10-06

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Kyoto Prefectural University of Medicine

Phase 3 Active not recruiting
160 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡